Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Mayo Clinic and SV Bio Enter Strategic Relationship on Genome Diagnostics and Interpretation

Published: Thursday, January 24, 2013
Last Updated: Thursday, January 24, 2013
Bookmark and Share
SV Bio’s turnkey solutions to support newly launched Individualized Medicine Clinic.

Mayo Clinic and Silicon Valley Biosystems (SV Bio) today announced a strategic collaboration for whole genome diagnostics and interpretation at the Mayo Clinic Center for Individualized Medicine and at Mayo Medical Laboratories. This strategic collaboration unites SV Bio’s proprietary genome interpretation solution with Mayo Clinic’s growing genome reference library and its commitment to individualized medicine, and will increase accessibility and clinical utility of next-generation sequencing for patients. SV Bio will provide clinical genome interpretation services and clinical decision support interfaces to Mayo Clinic, and Mayo’s Center for Individualized Medicine will contribute clinical and laboratory expertise and support. Financial details of the agreement were not disclosed.

“At Mayo Clinic, we are committed to integrating genomic medicine into the continuum of care for all of our patients,” says Gianrico Farrugia, M.D., director of the Mayo Clinic Center for Individualized Medicine. “The Individualized Medicine Clinic represents one of Mayo’s bold steps toward realizing the promise of these game-changing technologies and toward offering new hope to patients, including those with cancer and diagnostic dilemmas.”

While the rapidly declining cost of sequencing has been widely heralded and has led to varying degrees of clinical implementation at a handful of health care organizations, managing the sheer volume of data remains a bottleneck to widespread application of personalized medicine.

“Every human disease has a genetic component but, to date, medical providers have not been able to fully utilize this information to improve clinical outcomes,” says Dietrich Stephan, Ph.D., founder, president and CEO of SV Bio. “With the SV Bio platform, we’ve made the translation to a single assay — a full human genome — with the diagnostics rapidly and precisely happening in silico.” The SV Bio process is fully computerized and automated and reduces the time needed for clinically actionable genome interpretation from several weeks to a few minutes and puts the results in the provider’s hands at the point of care.

The goal of the collaboration is to unlock the full potential of next-generation sequencing and open these technologies to every patient. SV Bio’s turnkey genomics interpretation solutions query a patient’s genome at the point of care and distill the biological data into a concise, actionable report that physicians can use to make faster, more informed decisions. Mayo Clinic will provide medical and scientific expertise to help ensure patients receive the maximum benefit.

“We are now able to take data from any next-generation sequencer and determine with clinical grade sensitivity and specificity which variants within a patient’s DNA sequence are influencing a disease or condition, and rapidly provide a report for the clinician that is clear and actionable,” Dr. Stephan says. “This level of speed, accuracy and integration into the clinical work flow is not only a first for molecular testing, but also a sea change in the application of next-generation sequencing with no compromise of quality in clinical diagnostics.”

As part of the collaboration, Mayo Medical Laboratories, the reference laboratory that provides services worldwide, and SV Bio will work together to refine approaches to clinical genome interpretation.

“In our laboratories, we are rapidly adopting and implementing next-generation sequencing as a platform upon which we will be providing cutting-edge genome-based testing,” says Franklin Cockerill, M.D., president of Mayo Medical Laboratories. “This collaboration with SV Bio furthers our mission of bringing the latest diagnostic technologies to health care providers around the world.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
New Imaging Method Reveals Nanoscale Details about DNA
Enhancement to super-resolution microscopy shows orientation of individual molecules, providing a new window into DNA’s structure and dynamics.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Scoliosis Linked to Disruptions in Spinal Fluid Flow
A new study in zebrafish suggests that irregular fluid flow through the spinal column brought on by gene mutations is linked to a type of scoliosis that can affect humans during adolescence.
A New Tool Brings Personalized Medicine Closer
Scientists from EPFL and ETHZ have developed a powerful tool for exploring and determining the inherent biological differences between individuals, which overcomes a major hurdle for personalized medicine.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!